Patients n | 127 | 103 | 88 |
Age at enrolment years | 66.8±8.6 | 66.7±8.7 | 66.9±8.9 |
Female sex | 59 (46.5%) | 45 (43.7%) | 37 (42.0%) |
Smoking history pack-years | 47.0 (33.7–60.0) | 50.4 (34.0–60.0) | 50.0 (33.5–58.5) |
Medication for COPD | 127 (100%) | 103 (100%) | 88 (100%) |
Influenza vaccination during previous year | 114 (89.8%) | 94 (91.3%) | 82 (93.2%) |
Pneumococcal vaccination during previous year | 12 (9.4%) | 10 (9.7%) | 8 (9.1%) |
COPD status by GOLD stage | | | |
Mild | 0 (0%) | 0 (0%) | 0 (0%) |
Moderate | 57 (44.9%) | 46 (44.7%) | 42 (47.7%) |
Severe | 51 (40.2%) | 44 (42.7%) | 37 (42.0%) |
Very severe | 19 (15.0%) | 13 (12.6%) | 9 (10.2%) |
BODE index | 4 (2–6) | 4 (2–5) | 4 (2–5) |
TLCO predicted/actual mmol·kPa−1·min−1 | 7.9 (7.2–8.8)/4.5 (3.4–5.8) | 7.9 (7.4–9.0)/4.5 (3.5–6.1) | 8.0 (7.4–8.9)/4.5 (3.6–6.0) |
Subjects reporting exacerbations in 12 months before study start | | | |
One exacerbation | 28 (22.0%) | 21 (20.4%) | 20 (22.7%) |
Two exacerbations | 37 (29.1%) | 30 (29.1%) | 28 (31.8%) |
Three exacerbations | 25 (19.7%) | 22 (21.4%) | 17 (19.3%) |
Four or more exacerbations | 37 (29.1%) | 30 (29.1%) | 23 (26.1%) |
Exacerbations in preceding 12 months | 3.1±2.3/2 (2–4) | 3.2±2.4/3 (2–4) | 3.1±2.4/2 (2–4) |
Exacerbations in preceding 12 months according to severity | | | |
Mild | 0.5±1.2 | 0.4±1.2 | 0.5±1.3 |
Moderate | 2.3±1.9 | 2.5±2.0 | 2.3±2.0 |
Severe | 0.4±0.6 | 0.3±0.6 | 0.3±0.5 |
FEV1 after bronchodilator use % predicted | 46.4±15.2 | 46.7±14.6 | 47.7±14.1 |